<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034359</url>
  </required_header>
  <id_info>
    <org_study_id>ACH443-003</org_study_id>
    <nct_id>NCT00034359</nct_id>
  </id_info>
  <brief_title>Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection</brief_title>
  <official_title>A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV)&#xD;
      activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with&#xD;
      chronic hepatitis B infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the safety and antiviral activity of 3 dose levels of ACH-126,443 versus&#xD;
      lamivudine and placebo over 12 weeks of treatment in the population is described.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">79</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-126,443</intervention_name>
    <other_name>beta-L-Fd4C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) infection, known to be hepatitis B surface antigen&#xD;
             positive ≥ 6 months.&#xD;
&#xD;
          -  Plasma HBV deoxyribonucleic acid level ≥ 100,000 copies/milliliter.&#xD;
&#xD;
          -  Hepatitis B e-antigen positive.&#xD;
&#xD;
          -  Human immunodeficiency virus negative.&#xD;
&#xD;
          -  Basic hematologic and chemistry parameters within acceptable limits (defined in&#xD;
             protocol).&#xD;
&#xD;
          -  No need for excluded medications.&#xD;
&#xD;
          -  Participants of reproductive capability must have utilized 2 approved forms of birth&#xD;
             control, one of which must have been barrier protection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Human immunodeficiency virus infection.&#xD;
&#xD;
          -  Hepatitis C co-infection.&#xD;
&#xD;
          -  Concurrent systemic antiviral treatment.&#xD;
&#xD;
          -  Previous antiviral treatment for HBV infection within 6 months prior to randomization&#xD;
             or treatment with lamivudine for more than 6 months at any time in the past.&#xD;
&#xD;
          -  Previous therapy with agents with significant systemic myelosuppressive or cytotoxic&#xD;
             potential within 3 months of study start or the expected need for such therapy at&#xD;
             study start.&#xD;
&#xD;
          -  Alcohol abuse.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Inability to tolerate oral medication.&#xD;
&#xD;
          -  Aspartate aminotransferase &gt; 7.0 times the upper limit of normal.&#xD;
&#xD;
          -  Alanine aminotransferase &gt; 7.0 times the upper limit of normal.&#xD;
&#xD;
          -  Any clinical condition or prior therapy that, in the Investigators opinion, would make&#xD;
             the participant unsuitable for the study or unable to comply with the dosing&#xD;
             requirements.&#xD;
&#xD;
          -  Use of any investigational drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Belgrade</city>
        <country>Former Yugoslavia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Novi Sad</city>
        <country>Former Yugoslavia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Former Yugoslavia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 26, 2002</study_first_submitted>
  <study_first_submitted_qc>April 26, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2002</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E-antigen Positive</keyword>
  <keyword>Treatment-naive Chronic Hepatitis B</keyword>
  <keyword>Achillion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

